SLU-PP-332 (also referred to as "SLUPP") is an experimental small-molecule compound often described in the scientific literature as an "exercise mimetic." It is a synthetic agonist of estrogen-related receptors (ERRα, ERRβ, and ERRγ), nuclear receptors involved in the regulation of mitochondrial function, oxidative metabolism, and energy expenditure.
Key Scientific Facts About SLU-PP-332
Mechanism of Action:
SLU-PP-332 activates metabolic pathways associated with aerobic exercise adaptation, leading skeletal muscle tissue to exhibit molecular and transcriptional responses similar to those observed during endurance training. These pathways promote increased energy expenditure and fatty acid oxidation without directly affecting appetite regulation.
Preclinical Findings:
In animal models of obesity, SLU-PP-332 has been reported to:
Reduce fat mass by approximately 12% within one month
Increase muscular endurance by nearly 50%
Improve glucose tolerance and metabolic efficiency
Current Development Status:
SLU-PP-332 is not approved for human use. To date, no clinical trials in humans have been conducted, and therefore its safety profile, toxicity, pharmacokinetics, and long-term effects remain unknown.
Risks and Limitations:
Although considered scientifically promising for the study of obesity, metabolic dysfunction, and muscle atrophy, any non-research use is regarded as unsafe and unauthorized. Furthermore, SLU-PP-332 does not replicate the full physiological benefits of physical exercise, including effects on psychological health, bone density, joint integrity, or neuromuscular coordination.
For research use only – Intended exclusively for qualified professionals conducting scientific research.